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Jingchun Jin1,4†, Tiefeng Jin1,2†, Meiling Quan1,2, Yingshi Piao2,3 and Zhenhua Lin1,2*Abstract
Background: Ezrin is a cytoskeletal protein that is involved in tumor growth and invasion. It has been suggested
that Ezrin expression plays an important role in tumor metastasis. This study is aimed to investigate the
clinicopathological significance of Ezrin overexpression in gastric adenocarcinomas.
Methods: Ezrin protein expression was examined by immunohistochemistry in 26 normal gastric mucosa,
32 dysplasia, and 277 gastric adenocarcinomas. The relationship between Ezrin expression and the
clinicopathological features of gastric cancers was analyzed. In addition, a gastric cancer cell line, MKN-1, was
also used for immunofluorescence staining to evaluate the distribution of Ezrin protein.
Results: Ezrin protein located in the cytoplasm and/or membrane in the migrating gastric cancer cells, and it
mainly concentrated at the protrusion site; however, only cytoplasmic distribution was observed in the
non-migrating cancer cells by immunofluorescence staining. The positive rate of Ezrin protein expression was
significantly higher in gastric adenocarcinoma and dysplasia compared with that in the normal gastric mucosa.
Moreover, expression frequency of Ezrin protein increased significantly in lymph node metastasis and late clinical
stages. Consistently, strong expression of Ezrin was significantly correlated with poor prognosis of gastric cancer.
Conclusion: The detection of Ezrin expression can be used as the marker for early diagnosis and prognosis of
gastric adenocarcinoma.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/2303598677653946
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Gastric cancer is one of the most fatal malignant tumors
worldwide. The poor prognosis is associated with
extensive local invasion and/or regional lymph node me-
tastasis [1]. Local recurrence remains the cause of
cancer-related deaths after resection in a substantial pro-
portion of patients with gastric cancer. Therefore, estab-
lishing reliable criteria to predict recurrence and to
identify the tumors is of great interest not only for
understanding the molecular and cellular processes* Correspondence: zhlin720@ybu.edu.cn
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reproduction in any medium, provided the orinvolved in tomorigenesis, but also for searching the
possible new therapeutic molecular targets [2].
Tumor metastasis starts with breakdown of epithelial
integrity, followed by malignant cells invading into the
surrounding stroma and lymphovascular space, by which
tumor cells travel to distant target organs [3,4]. Cell ad-
hesion molecules and actin cytoskeleton play a crucial
role in tumor metastasis [5,6]. The primary mechanism
for most types of cell migration is the actin cytoskeleton
remodeling [7]. The cytoskeletal protein Ezrin is a mem-
ber of the Ezrin-Radixin-Moesin (ERM) family which is
linked to aggressive tumor behavior by involving all
stages of tumor metastasis [7,8] including cell adhesion,
survival, motility, and signal transduction [9-11].
Recent publications showed that Ezrin is strongly
expressed in a variety of invasive cancers, including
osteosarcoma, melanoma, soft tissue sarcoma, pancreaticThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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breast cancers [2,11-17]. There is accumulating evidence
suggesting that Ezrin is a metastatic determinant and a
key component in tumor metastasis, however, its exact
role in gastric cancer is still unknown. Bal et al. [18]
reported that there was a negative correlation between
Ezrin and lymph node metastasis, lymphovascular space
invasion, and perineural invasion in all gastric carcin-
omas, but was not statistically significant (P > 0.05),
while no association with depth of invasion, tumor loca-
tion, tumor size and distant metastasis (P > 0.05). How-
ever, Zhao et al. [19] and Li et al. [20] reported that
positive expression of Ezrin correlated with age, tumor
size, location, differentiation stage, depth of invasion,
vessel invasion, lymph node and distant metastasis, and
TNM stage (P < 0.05). In present study, we therefore
aimed to investigate the Ezrin protein expression in
human gastric adenocarcinoma and its precancerous
lesions, and to explore the exactly relation of Ezrin ex-
pression to the clinical outcomes and the histological
parameters of gastric cancers.
Materials and methods
Clinical samples
Total 335 tissue samples, including 277 cases of gastric
adenocarcinomas, 32 cases of dysplasia and 26 of normal
gastric tissues, were collected from Shanghai Outdo Bio-
tech Co. Ltd. (Outdo Biotech) and Department of Path-
ology, The Third Affiliated People’s Hospital of Shanghai
Jiaotong University. All tissues were routinely fixed in
10% buffered formalin and embedded in paraffin blocks.
The study protocol was approved by the institutional re-
view board of Yanbian University Medical College.
The pathological parameters, including age, gender,
histological types, differentiation, the presence of nodal
metastasis, clinical stage and disease free survival, were
carefully reviewed in all of 277 gastric adenocarcinomas.
The patients’ age ranged from 36 to 78 yr with a mean
age of 51.7 yr. The male to female ratio was 164:113. Of
the 277 gastric adenocarcinomas encompassed 39 cases
of TNM stage 0, 98 cases of TNM stage I (TNM stage
IA= 47, TNM stage IB = 51), 75 cases of TNM stage II,
59 cases of TNM stage III, and 6 cases of TNM stage
IV. In which, 85 cases were well differentiated adenocar-
cinoma, 103 cases as moderately differentiated, 59 cases
as poorly differentiated, 5 cases as undifferentiated, 9
cases as signet ring cell carcinomas, and 16 cases as mu-
cinous adenocarcinoma. For the Lauren types, 117 cases
were intestinal type, 139 cases as diffuse type, and 21
cases as mixed types. TNM staging was assessed accord-
ing to the staging system established by the American
Joint Committee on Cancer (AJCC) [21]. Of the 277 gas-
tric adenocarcinomas, 151 cases were lymph node (LN)
metastasis negative, and 126 cases were LN meatastasispositive. In total 277 of gastric adenocarcinomas, 54.9%
(152/277) of cases were more than three years of disease
free survival. Additionally, the normal gastric mucosa
tissues were obtained from the resection margins of rad-
ical specimen of gastric cancer.Immunofluorescence staining for Ezrin protein in cancer
cells in vitro
Gastric cancer cell line MKN-1 was grown on coverslips
to 100% confluence, and then continued to culture with
FBS free medium for 24 hours after being scratched by a
new 200 μl pipette tip for searching the migrating cells.
The cells were then fixed with 4% paraformaldehyde for
10 minutes and permeabilized with 0.5% TritonX-100
for 10 minutes after 24 hours. Blocking was performed
with 3% Albumin Bovine V (A8020, Solarbio, Beijing,
China) for one hour at the room temperature. After
washing with PBS, cells were incubated with antibody
against Ezrin (1:100, #3145, Cell Signaling Technology,
Boston, USA) for two hours, and followed the incuba-
tion by Alexa FluorW488 goat anti-rabbit IgG (H+C)
(A11008, Invitrogen, USA) for one hour at room
temperature. After washing with PBS, the cells were coun-
terstained with 49-6-diamidino-2-phenylindole (DAPI)
(C1006, Beyotime, Shanghai, China), and the coverslips
were mounted with Antifade Mounting Medium (P0126,
Beyotime, Shanghai, China). Finally, the immunofluores-
cence signals were visualized and recorded by Leica SP5II
confocal microscope.Immunohistochemistry for Ezrin protein in
paraffin-embedded tissues
Dako LSAB kit (Dako, Glostrup, Denmark) was used for
immunohistochemistry. And the serial 4 μm-thick tissue
sections were prepared on silane-coated slides (Sigma, St
Louis, MO, USA), and deparaffinized, rehydrated and
incubated with 3% H2O2 in methanol for 5 minutes at
room temperature to eliminate endogenous peroxidase
activity. The antigen was retrieved at 95°C for 20 minutes
by placing the slides in 10 mM sodium citrate buffer
(pH 6.0). The slides were then incubated with primary
antibody Ezrin (1:50, #3145, Cell Signaling Technology,
Boston, USA) at 4°C for overnight. After incubation at
room temperature for 30 minutes with biotinylated sec-
ondary antibody, the slides were incubated with
streptavidin-peroxidase complex at room temperature
for 30 minutes. Immunostaining was developed by using
chromogen, 3,3'-diaminobenzidine, and counterstained
with Mayer's hematoxylin. Rabbit IgG isotope used as
the control and the result is negative. Also, the positive
tissue sections were processed omitting the primary
antibody as negative controls.
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All slides were scored independently by two investigators
(Lin Z and Piao Y) being blinded to all clinical data. The
interpretation criteria were described previously by
Elzagheid A et al. [22]. Briefly, lymphocytes served as a
reference for strong immunoreactivity (Figure 1),
and the immunoreactivity was graded into four categories:
+++ (score 3) = similar to the lymphocyte staining; ++
(score 2) = less than +++; + (score 1) = distinguishable
from the background staining; and – (score 0) = com-
pletely negative. Only the cytoplasmic and membranous
expression was considered as positive staining and the
strong positive means ‘++’ and ‘+++’ positive cells.
Statistical analysis
Statistical analysis was performed using the Chi-square
(x2-test) test and Mean-Whitney test of SPSS software
program for windows, version 17.0 (SPSS, Chicago,
USA). P-value less than 0.05 considered significant.
Results
The characteristics of Ezrin protein localization and
distribution
To observe the localization of Ezrin protein in migrating
and non-migrating cancer cells, the cultured MKN-1
gastric cancer cells were scratched by a new 200 μl pip-
ette tip (Figure 1), and then the immunofluorescence
staining for Ezrin protein was done. It was found that
Ezrin protein located at the cytoplasm and/or membrane
in the migrating MKN-1 cells, and mainly concentrated
at the protrusion site; however, only cytoplasmicFigure 1 Immunofluorescence staining for Ezrin protein in
cultured MKN-1 cells (red for Ezrin protein & blue for DAPI).
Ezrin protein located in the cytoplasm and membrane in cultured
MKN-1 migrating gastric cancer cells, and it mainly concentrated at
the membranous protrusion site (Figure 1, 24 h); however, Ezrin
protein only located at the cytoplasm of non-migrating cancer cells
(Figure 1, 0 h).distribution was observed in the non-migrating MKN-1
cells by immunofluorescence staining (Figure 1). For the
tissue sections, diffusely and strongly positive signals for
Ezrin protein was detected in the cytoplasm of gastric
cancer cells, however negative or scattered positive cells,
mainly basal reserve cells, was observed in the normal
gastric epithelia by immunohistochemistry. Interestingly,
single scattered cancer cells or invasive cancer loci at the
stroma frequently showed strongly and most intense
immunoreactivity for Ezrin protein (Figure 2).
Correlation between Ezrin protein overexpression and
clinical parameters of gastric cancers
Ezrin protein showed higher positivity in gastric adeno-
carcinoma (score 1, 79.8%, 221/277; score 2, 60.6%, 168/
277) compared with the adjacent normal gastric mucosa
(score 1, 19.2%, 5/26; score 2, 0, 0/26). Also, Ezrin pro-
tein was strongly positive in gastric dysplasia (score 1,
65.6%, 21/32; score 2, 37.5%, 12/32) on immunohisto-
chemistry, which was also significantly higher than nor-
mal gastric tissues (score 1, 19.2%, 5/26; score 2, 0%,
0/26). Similarly, Lauren intestinal (65.8%, 77/117) and
diffuse (61.2%, 85/139) types of gastric cancer also
determined strongly expression rate of Ezrin protein
compared to the mixed type (28.6%, 6/21) cases
(P < 0.05). (Figures 2 & 3, Tables 1 & 2).
Additionally, Ezrin protein overexpression was signifi-
cantly correlated with the lymph node metastasis of gas-
tric adenocarcinoma. The strongly positive rates of Ezrin
were 35.1% (53/151) and 91.3% (115/126) in non-
metastatic and metastasic carcinoma of stomach, re-
spectively (P<0.01). For the TNM clinical stages, Ezrin
positive rate was only 35.8% (49/137) in early clinical
stage (35.9% in Stage 0, 25.5% in stage IA and 45.1% in
stage IB) of gastric cancer, however significantly higher
in late stage cases (85.0%, 119/140) (78.7% in Stage II,
91.5% in stage III, and 100% in stage IV), and the differ-
ence was statistically significant (P<0.05). Also, the
strongly positive rate of Ezrin protein expression was
significantly higher in <3 years disease free survival cases
(92.0%, 115/125) than it in ≥3 years disease free survival
cases (34.9%, 53/152) (P < 0.01). However, Ezrin protein
expression level was not correlated with the patient age,
gender, histological type status of gastric adenocarcin-
oma (P>0.05) (Figure 3, Table 2).
Discussion
Gastric cancer is the one of most common malignant
tumor worldwide. Despite effective control of the primary
tumor and both neoadjuvant and adjuvant chemotherapy,
the development of metastases is still the common cause
of death in gastric cancer patients [23,24]. The develop-
ment of new and effective treatments based on the well
understanding of metastasis biology is needed.
Figure 2 Immunoreactivity for Ezrin protein in gastric lesions. Immunohistochemical staining for Ezrin protein in the tissuearray of gastric
adenocarcinoma (A). Scattered positive cells (arrows) for Ezrin protein were seen at the cytoplasm of basal reserve cells in gastric normal mucosa
(B-a) (200×). The gastric cancer cells showed strongly and diffusely positive staining for Ezrin protein (B-b) (200×). Single scattered cancer cells
and invasive cancer loci at the stroma showed intense immunoreactivity for Ezrin protein (arrows) (B-c) (200×).
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and the total length of mRNA is 3166 bp, encoding 585
amino acids. Ezrin has been shown to bind directly to
PI3K and influence many signaling pathways that affect
cellular functions related to tumorigenesis and metastasis,
including MAPK-ERK1/2, PI3K-Akt and Rho pathways.
Recently, increasing reports also showed that the critical
functions of Ezrin are the regulation of cell shape, motility,
adhesion and signal transduction, all of which are import-
ant for tumor development and progression [25].
Wang et al. [26] reported that the inhibition of Ezrin
expression clearly inhibited the migration and invasion
of the human gastric cancer cell line SGC-7901, and
increased both cell adhesion and sensitivity to
camptothecin-induced apoptosis. Overexpression of
Ezrin also promoted cell protrusion, microvillus forma-
tion, anchorage-independent growth, motility and inva-
sion in the pancreatic cancer cell line, MiaPaCa-2 [14].
Since then, Ezrin expression has been linked to clinical
outcome and prognosis in many cancer types includingosteosarcoma, pancreatic carcinoma, hepatocellular car-
cinoma, and breast carcinoma [14-17].
As a member of ERM protein family, Ezrin functions
as a linker protein connecting the actin cytoskeleton
(Ezrin C-terminus) to integral plasma membrane pro-
teins (Ezrin N-terminus) [27]. It is proposed that Ezrin
exists in a dormant form in which the C-terminal tail
binds to and masks the N-terminal FERM domain [28].
Therefore, amino-terminal Ezrin interactions are critical
in determining not only the repertoire of proteins Ezrin
can interact with but also the corresponding cellular
functions that may be positively or negatively affected
[27]. This linkage to the cell membrane allows the cells
to physically engage and potentially sense the tumor
microenvironment [27,28]. Elzagheid et al. [22] reported
that Ezrin was predominantly expressed at the apical cell
membrane in a polarized fashion in normal colonic epi-
thelium. In contrast, Ezrin expression in the cancer cells
was typically cytoplasmic. In the present study, Ezrin
protein was found to locate in the cytoplasm and/or
Figure 3 Ezrin protein showed significantly higher positivity in gastric adenocarcinoma and dysplasia compared with the adjacent
normal gastric mucosa (A), and its expression level was significantly higher in the late stage (Stage II, Stage III, and Stage IV) of gastric
cancers than it in the early stage (Stage 0, Stage IA, and Stage IB) cases (B). Moreover, strongly expression of Ezrin protein was detected in
Lauren intestinal and diffuse type of gastric adenocarcinomas than it in the mixed type cases (C). Ezrin protein overexpression showed closely
correlation to the metastatic status (D) and disease free survival of gastric adenocarcinoma (E).
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and it mainly concentrated at the protrusion site of
MKN-1 gastric cancer cells; however, Ezrin protein
located only in the cytoplasm in non-migrating cells
in vitro by immunofluorescence staining (Figure 1). By
the immunohistochemistry, the diffusely and strongly
positive signals for Ezrin protein was detected in the
cytoplasm of gastric cancer cells; however, negative or
scattered positive cells (mainly basal reserve cells) was
observed in the cytoplasm of normal gastric epithelia,









- + ++ +++
Gastric adenocarcinoma 277 56 53 102 66 79.8%** 60.6%**
Dysplasia 32 11 9 12 0 65.6%* 37.5%*
Normal mucosa 26 21 5 0 0 19.2% 0
Compared with normal mucosa *P < 0.05, **P < 0.01. Strongly positive: ++
and +++.predominantly cytoplasmic distribution in non-
migrating cancer or normal cells, but mainly membran-
ous distribution in the migrating cells in vitro. This is
consistent with the previous reports in other epithelial
human tumors. However, apical localization of Ezrin
protein was seen neither in gastric carcinoma nor in
normal gastric epithelia by immunohistochemistry. More
interestingly, scattered single cancer cells at the stroma
frequently showed stronger and most intense immunor-
eactivity in this study, and similar observations was
reported previously in colorectal cancers by Elzagheid
et al. [22] and endometrioid carcinomas by Köbel et al.
[29] and Yasuoka et al. [30]. These data indicated that
Ezrin might be essential for the processes of gastric can-
cer cells, including the determination of cell shape, po-
larity and formation of surface structures, motility, and
integration of membrane transport with signaling path-
ways. But the detailed mechanism needs to be explored
by the further study.
Recently, it has been shown that Ezrin plays a pivotal
role in the progression of gastrointestinal carcinoma
[2,18-20,22]. Elzagheid et al. [22] reported that Ezrin
Table 2 Relationship between Ezrin protein
overexpression and clinicopathological features of gastric
adenocarcinoma







<50 96 60 (62.5%) NS
51-69 181 92 (50.8%)
≥70 29 16 (55.2%)
Gender NS
Male 164 102 (62.2%)
Female 113 66 (58.4%)
Lauren Types <0.05, a
Intestinal type 117 77 (65.8%)
Diffuse type 139 85 (61.2%)
Mixed type 21 6 (28.6%)
WHO’s Histological Types NS
Well-diff. ade. 85 42 (49.4%)
Moderately-diff. ade. 103 54 (52.4%)
Poorly-diff. ade. 59 50 (84.7%)
Undifferentiated ade. 5 3 (60.0%)
Signet ring cell carcinoma 9 5 (55.6%)
Mucinous ade. 16 14 (87.5%)
LN Metastasis <0.01
Negative 151 53 (35.1%)
Positive 126 115 (91.3%)
Clinical Stage <0.05, b
0 39 14 (35.9%)
IA 47 12 (25.5%)
IB 51 23 (45.1%)
II 75 59 (78.7%)
IIIA 59 54 (91.5%)
IV 6 6 (100%)
Disease Free Survival <0.01
≥3 years 152 53 (34.9%)
<3 years 125 115 (92.0%)
ade.: Adenocarcinoma; diff.: differentiated; NS: not significant.
* Strongly positive: ++ and +++.
a: Intestinal & Diffuse types vs Mixed type.
b: Stage 0+ Stage IA + Stage IB vs Stage II + Stage IIIA + Stage IV.
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Ezrin expression might provide clinically valuable infor-
mation in predicting the biological behavior of colorectal
cancer. Zhao et al. [19] reported that overexpression of
Ezrin promoted gastric cancer cell invasion, whereas in-
activating Ezrin function with small interference RNA
caused reduced cell invasion, indicating a potential role
of Ezrin in regulating the progression to invasive gastriccancer. In the present study, 277 cases of gastric adeno-
carcinomas, 32 of dysplasia, and 26 of normal gastric
mucosa were investigated, and it was found that Ezrin
expression was significantly up-regulated in gastric can-
cers and dysplasia compared with normal gastric mu-
cosa, however no difference was found between gastric
cancer and dysplasia, indicating that Ezrin protein over-
expression could be used as the early diagnostic marker
for gastric cancer and its precancerous disease.
It is well known that TNM staging system according
to The American Joint Committee on Cancer (AJCC)/
International Union against Cancer (UICC) produced
the most reliable system for predicting the survival of
patients. Furthermore lymphatic and vascular invasion
were also considered as poor prognostic indicators [31].
Limited reports suggest that Ezrin may be a useful prog-
nostic and survival indicator for gastric cancers. Zhao
et al. [19] and Fan et al. [2] demonstrated that Ezrin was
required for the invasion of gastric cancer cells. How-
ever, Bal et al. [18] reported that no statistically signifi-
cance was found about the correlation of ezrin
overexpression and lymph node metastasis, lymphovas-
cular space invasion, and distant metastasis. Here we
found that the strongly positive rate of Ezrin protein ex-
pression was significantly higher in metastatic gastric
cancer (91.3%) than it in non-metastatic cancer cases
(35.1%) (P < 0.01). For the TNM clinical stages, the
strongly positive rate of Ezrin was lower in Stage 0
(35.9%) and stage I (Stage IA: 25.5%; Stage IB: 45.1%)
compared with Stage II (78.7%), Stage III (91.5%) and
Stage IV (100%), the difference was statistically signifi-
cant (P < 0.05), demonstrating that Ezrin protein overex-
pression was strongly correlated with the lymph node
metastasis and clinical stage of gastric cancers. Addition-
ally, Li et al. [20] reported that for 436 gastric cancer
patients with stage I, II or III disease, the 5-year survival
rate for those with high Ezrin expression were signifi-
cantly lower than in patients with low expression. Zhao
et al. [19] also reported that the survival rate of patients
with Ezrin or c-Met positive gastric cancers were signifi-
cantly lower than those in patients with Ezrin or c-Met
negative tumors (P<0.05). However, here we also found
that the strongly positive rate of Ezrin protein expression
was significantly higher in <3 years disease free survival
cases (92.0%) than it in 33 years disease free survival
cases (34.9%) (P<0.01). All above data strongly indicated
that Ezrin could be regarded as a potential prognostic
factor in gastric cancers.
Moreover, Lam et al. [32] reported that among 150
gastric cancer cases, 33 (22.0%) cases showed low Ezrin
expression, 92 (61.3%) cases showed moderate Ezrin ex-
pression and 25 (16.7%) cases showed high Ezrin expres-
sion. Ezrin expression was associated with Lauren type
and differentiation but not correlated with the patients’
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Ezrin positive expression is correlated with age, tumor
size and location, grading and poor prognosis. In the
present study, higher strongly expression rate of Ezrin
protein was detected in intestinal type (65.8%) and dif-
fuse type (61.2%) of gastric cancer than that in the
mixed type (28.6%) cases. But Ezrin protein expression
level was not correlated with the patient age, gender,
WHO’s histological type status of gastric carcinomas
(P>0.05). This is consistent with Lam’s report, but it
needs the further study to verify.
All above data point to the importance of Ezrin not
only as a useful marker of early diagnosis and prognosis
but also as a potential therapeutic target in gastric
adenocarcinoma. The high frequency of Ezrin expression
suggests a central role in gastric cancer biology, though
the further study needs to be investigated for exploring
the mechanism in detail. In summary, the detection of
Ezrin protein expression could be used as an early diag-
nostic marker of gastric cancer and its precancerous dis-
ease, and Ezrin overexpression could predict the poor
prognosis of gastric adenocarcinoma, suggesting that
Ezrin might be a potential molecular target for gastric
adenocarcinoma therapy.
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